EBS Q4 2022 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$330M-54.3% YoY

Gross Profit

$114M34.6% margin

Operating Income

-$55M-16.7% margin

Net Income

-$67M-20.3% margin

EPS (Diluted)

$-1.76

QoQ Revenue Growth

+37.6%

Cash Flow

Operating Cash Flow

$93M

Free Cash Flow

$47M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$3.2B

Total Liabilities

$1.8B

Stockholders' Equity

$1.4B

Cash & Equivalents

$643M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$330M	$723M	-54.3%
Gross Profit	$114M	$428M	-73.3%
Operating Income	-$55M	$277M	-119.9%
Net Income	-$67M	$189M	-135.4%

Revenue Segments

Product

$306M92%

Contract Development And Manufacturing

$18M5%

Contracts and Grants

$7M2%

Geographic Segments

UNITED STATES

$603M100%